A milk patch is being developed for IgE mediated cow’s milk allergy. We have spoken about patch treatment previously regarding peanut allergy.
Viaskin Peanut Patch Safety Results
Peanut Patch (Viaskin) for peanut allergy
Cow’s milk allergy affects approximately 2-3% of infants worldwide, often presenting with symptoms ranging from mild to severe anaphylaxis. The primary treatment strategy has been strict avoidance of cow’s milk proteins and the use of epinephrine for severe reactions. However, recent advancements in immunotherapy have introduced the Viaskin patch as a promising alternative for inducing tolerance in CMA patients.
So far the peanut patch has not come to market, but there have been 2 treatments FDA approved for food allergy. Palforzia for peanut allergy and Xolair for food allergies in general.
Palforzia (formerly AR101) and peanut allergy
The Viaskin patch utilizes epicutaneous immunotherapy (EPIT), where allergens are delivered to the immune system through intact skin. The patch contains cow’s milk proteins and is applied to the skin, allowing for gradual exposure to the allergen. This method aims to modulate the immune response, promoting tolerance through the activation of regulatory T cells and reduction of IgE-mediated allergic reactions.
No approved treatment exists for cow milk allergy currently. A study was published in JAMA Pediatrics, this was a phase 1/2 randomized trial assessing the safety and efficacy of different doses in children with cow’s milk allergy. The Viaskin patch delivers small amounts of cow’s milk protein daily via a patch directly applied to the skin. After 12 months of treatment the highest response rate was observed in the 300 microgram dose (as opposed to the 150 and 500).
The Viaskin milk patch has shown promise in increasing the threshold of reactivity, thereby reducing the risk of accidental reactions and improving the quality of life for CMA patients.
The Viaskin milk patch has been generally well-tolerated in clinical trials. The most common adverse events reported were local skin reactions at the site of application, including erythema and pruritus. These reactions were typically mild to moderate and resolved spontaneously. No severe systemic allergic reactions were attributed to the Viaskin patch, highlighting its safety as an immunotherapy option for CMA.
The Viaskin Cow Milk Patch offers a novel and effective approach to desensitizing children with cow’s milk allergy. By gradually introducing cow’s milk proteins through the skin, the Viaskin patch has the potential to improve tolerance and reduce the risk of severe allergic reactions. Continued research and clinical trials will be crucial in further understanding its long-term benefits and establishing its place in the management of cow’s milk allergy.
Cow’s milk oral immunotherapy is also an option as well, studies have shown that it has a strong long term adherence. This could be because dairy products are in numerous attractive food items (chocolate, ice cream, pizza).

